Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLATINUM: INE963 + Cipargamin in Uncomplicated Plasmodium Falciparum Malaria
NCT07811882Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2025
- Primary completion
- Jun 2026
- Countries
- 7
01
Overview
A Phase 2 trial of INE963, cipargamin in Plasmodium falciparum malaria, sponsored by Novartis. Started Oct 2025; status: completed.
02
Drugs
INE963cipargamin
03
Conditions
Plasmodium falciparum malaria
Beyond the preview
Go deeper on NCT07811882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07811882.